Anyone still looking for a CD47? Zai Lab shelves PhI program after reviewing 'competitive landscape'
2022-08-10
抗体AACR会议
Over the past few years, the promise of blocking CD47 — a “don’t eat me” signal co-opted by cancer cells — has sent drugmakers big and small into a frenzy. But one biotech is now bowing out.
Zai Lab is deprioritizing ZL-1201, its CD47 inhibitorCD47 inhibitor, scrapping plans for a Phase II trial. It will now “pursue out-licensing opportunities,” the company said in its
Q2 update
. The decision was based on a review of the competitive landscape, it added, without going into further details.
The move comes as the fever pitch appears to have died down, with
clinical holds
on Gilead’s frontrunning candidate from its Forty Seven buyout, magrolimab, throwing cold water on the field.
Just weeks ago, AbbVie terminated an exploratory study of a CD47 drug it got from a $3 billion alliance with I-Mab, citing “strategic reasons.” It had tested lemzoparlimab as both monotherapy or in combo with other drugs as a multiple myeloma treatment.
Like other later efforts, Zai Lab was familiar with the challenges of this space, especially on the safety side, going into the ZL-1201 program. As researchers wrote in an AACR
abstract
last year:
ZL-1201 was thus “engineered to reduce Fc-mediated antibody effector function,” and they reported that it did bind to CD47 while having a better safety profile than the benchmark antibody.
The company has a Phase I trial testing the drug in solid tumors, and it’s already decided on a recommended Phase II dose.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。